These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 9374514)

  • 61. Zn2+ binding to cysteine-rich domain of extracellular human immunodeficiency virus type 1 Tat protein is associated with Tat protein-induced apoptosis.
    Misumi S; Takamune N; Ohtsubo Y; Waniguchi K; Shoji S
    AIDS Res Hum Retroviruses; 2004 Mar; 20(3):297-304. PubMed ID: 15117453
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Cytotoxic effect on lymphocytes of Tat from human immunodeficiency virus (HIV-1).
    Benjouad A; Mabrouk K; Moulard M; Gluckman JC; Rochat H; Van Rietschoten J; Sabatier JM
    FEBS Lett; 1993 Mar; 319(1-2):119-24. PubMed ID: 8095908
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Fab'-induced folding of antigenic N-terminal peptides from intrinsically disordered HIV-1 Tat revealed by X-ray crystallography.
    Serrière J; Dugua JM; Bossus M; Verrier B; Haser R; Gouet P; Guillon C
    J Mol Biol; 2011 Jan; 405(1):33-42. PubMed ID: 21035463
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Molecular dynamics simulations on HIV-1 Tat.
    Pantano S; Tyagi M; Giacca M; Carloni P
    Eur Biophys J; 2004 Jul; 33(4):344-51. PubMed ID: 14608449
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Enhancement of antigen-induced T-cell proliferation by soluble CD26/dipeptidyl peptidase IV.
    Tanaka T; Duke-Cohan JS; Kameoka J; Yaron A; Lee I; Schlossman SF; Morimoto C
    Proc Natl Acad Sci U S A; 1994 Apr; 91(8):3082-6. PubMed ID: 7909158
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Doxorubicin inhibits Tat-dependent transactivation of HIV type 1 LTR.
    Jeyaseelan R; Kurabayashi M; Kedes L
    AIDS Res Hum Retroviruses; 1996 May; 12(7):569-76. PubMed ID: 8743082
    [TBL] [Abstract][Full Text] [Related]  

  • 67. The N-Terminal Region of HIV-1 Tat Protein Binds CD127 in Human CD8 T Cells to Target the Receptor for Down Regulation Through Tat's Basic Region.
    Sugden SM; MacPherson PA
    Curr HIV Res; 2015; 13(3):226-43. PubMed ID: 25986373
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Interferon alpha and Tat involvement in the immunosuppression of uninfected T cells and C-C chemokine decline in AIDS.
    Zagury D; Lachgar A; Chams V; Fall LS; Bernard J; Zagury JF; Bizzini B; Gringeri A; Santagostino E; Rappaport J; Feldman M; Burny A; Gallo RC
    Proc Natl Acad Sci U S A; 1998 Mar; 95(7):3851-6. PubMed ID: 9520456
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Signal transduction events induced or affected by inhibition of the catalytic activity of dipeptidyl peptidase IV (DP IV, CD26).
    Kähne T; Reinhold D; Neubert K; Born I; Faust J; Ansorge S
    Adv Exp Med Biol; 2000; 477():131-7. PubMed ID: 10849739
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Small HIV-1-Tat peptides inhibit HIV replication in cultured T-cells.
    Löhr M; Kibler KV; Zachary I; Jeang KT; Selwood DL
    Biochem Biophys Res Commun; 2003 Jan; 300(2):609-13. PubMed ID: 12504126
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Functional role of CD26 on human B lymphocytes.
    Bühling F; Junker U; Reinhold D; Neubert K; Jäger L; Ansorge S
    Immunol Lett; 1995 Feb; 45(1-2):47-51. PubMed ID: 7622187
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Induction of apoptosis in uninfected lymphocytes by HIV-1 Tat protein.
    Li CJ; Friedman DJ; Wang C; Metelev V; Pardee AB
    Science; 1995 Apr; 268(5209):429-31. PubMed ID: 7716549
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Transdominant mutants of I kappa B alpha block Tat-tumor necrosis factor synergistic activation of human immunodeficiency virus type 1 gene expression and virus multiplication.
    Beauparlant P; Kwon H; Clarke M; Lin R; Sonenberg N; Wainberg M; Hiscott J
    J Virol; 1996 Sep; 70(9):5777-85. PubMed ID: 8709193
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Docking studies reveal a selective binding of D-penicillamine to the transactivator protein of human immunodeficiency virus type 1.
    Demirhan I; Kanyalkar M; Chandra A; Doerr HW; Coutinho E; Loewer J; Saran A; Chandra P
    FEBS Lett; 2002 Apr; 516(1-3):43-6. PubMed ID: 11959100
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Spectroscopic investigations of HIV-1 trans-activator and related peptides in aqueous solutions.
    Klostermeier D; Bayer P; Kraft M; Frank RW; Rösch P
    Biophys Chem; 1997 Jan; 63(2-3):87-96. PubMed ID: 9108685
    [TBL] [Abstract][Full Text] [Related]  

  • 76. The HIV-1 Tat transactivator protein: a therapeutic target?
    Fulcher AJ; Jans DA
    IUBMB Life; 2003 Dec; 55(12):669-80. PubMed ID: 14769003
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Loss of G(1)/S checkpoint in human immunodeficiency virus type 1-infected cells is associated with a lack of cyclin-dependent kinase inhibitor p21/Waf1.
    Clark E; Santiago F; Deng L; Chong S; de La Fuente C; Wang L; Fu P; Stein D; Denny T; Lanka V; Mozafari F; Okamoto T; Kashanchi F
    J Virol; 2000 Jun; 74(11):5040-52. PubMed ID: 10799578
    [TBL] [Abstract][Full Text] [Related]  

  • 78. RNA conformation in the Tat-TAR complex determined by site-specific photo-cross-linking.
    Wang Z; Rana TM
    Biochemistry; 1996 May; 35(20):6491-9. PubMed ID: 8639596
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Using peptides to study the interaction between the p53 tetramerization domain and HIV-1 Tat.
    Gabizon R; Mor M; Rosenberg MM; Britan L; Hayouka Z; Kotler M; Shalev DE; Friedler A
    Biopolymers; 2008; 90(2):105-16. PubMed ID: 18189286
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Characterization of the solution conformations of unbound and Tat peptide-bound forms of HIV-1 TAR RNA.
    Long KS; Crothers DM
    Biochemistry; 1999 Aug; 38(31):10059-69. PubMed ID: 10433713
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.